ES2038847T3 - Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines. - Google Patents

Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.

Info

Publication number
ES2038847T3
ES2038847T3 ES198989830422T ES89830422T ES2038847T3 ES 2038847 T3 ES2038847 T3 ES 2038847T3 ES 198989830422 T ES198989830422 T ES 198989830422T ES 89830422 T ES89830422 T ES 89830422T ES 2038847 T3 ES2038847 T3 ES 2038847T3
Authority
ES
Spain
Prior art keywords
azt
inosiplex
aids
administration
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198989830422T
Other languages
English (en)
Inventor
Claudio De Simone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT8848388A external-priority patent/IT1235029B/it
Priority claimed from IT8848445A external-priority patent/IT1235033B/it
Priority claimed from IT8848444A external-priority patent/IT1235032B/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2038847T3 publication Critical patent/ES2038847T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LA ADMINISTRACION DE UNA MEZCLA FARMACEUTICA COMPUESTA DE INOSIPLEX INMUNOMODULADOR O COMPONENTES DE EL (ACIDO P-ACETAMIDOBENZOICO E INOSINA), Y CIDOVUDINA (3''-ACIDO-3''-DEOXITIMIDINA,AZT) HACE POSIBLE IMPORTANTES INCREMENTOS DE LOS NIVELES DE PLASMA BASAL Y DE LA VIDA MEDIA DEL PLASMA DE AZT EN UN PACIENTE SUFRIENDO DE SIDA. ESTO PERMITE REDUCIR LA DOSIS DE AZT ADMINISTRADA DIARIAMENTE (1200 MG POR DIA), DE ESTE MODO SE CONSIGUE UNA REDUCCION EN LA IMPORTANTE TOXICIDAD DEL AZT MIENTRAS QUE SE MANTIENE LA EFICACIA DE LA TERAPETICA DEL AZT. LA BAJA TOXICIDAD DE LA MEZCLA COMPARADA CON LA DEL AZT JUSTIFICA AHORA SOLO LA ADMINISTRACION DEL AZT PARA PACIENTES CON SINTOMAS HIV-SEROPOSITIVOS A QUIENES SU ADMINISTRACION HASTA LA FECHA HA SIDO JUZGADA NO ACONSEJABLE POR LA SERIA TOXICIDAD DEL AZT.
ES198989830422T 1988-09-28 1989-09-27 Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines. Expired - Lifetime ES2038847T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT8848388A IT1235029B (it) 1988-09-28 1988-09-28 Composizione farmaceutica comprendente inosiplex e zidovudina per il trattamento dell'aids e sindromi correlate
IT8848445A IT1235033B (it) 1988-10-12 1988-10-12 Composizione farmaceutica comprendente acido p-acetammidobenzoico e zidovudina per il trattamento dell'aids e sindromi correlate
IT8848444A IT1235032B (it) 1988-10-12 1988-10-12 Composizione farmaceutica comprendente inosina,acido p-acetammidobenzoico e zidovudina per il trattamento dell'aids e sindromi correlate

Publications (1)

Publication Number Publication Date
ES2038847T3 true ES2038847T3 (es) 1993-08-01

Family

ID=27273668

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198989830422T Expired - Lifetime ES2038847T3 (es) 1988-09-28 1989-09-27 Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.

Country Status (6)

Country Link
US (1) US5108993A (es)
EP (1) EP0362162B1 (es)
JP (1) JPH02142733A (es)
DE (1) DE68900926D1 (es)
ES (1) ES2038847T3 (es)
GR (1) GR3004419T3 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285232B6 (cs) * 1991-05-16 1999-06-16 Glaxo Group Limited Protivirové směsi
JP2669937B2 (ja) * 1993-02-22 1997-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノート シヤツプ ジドブジンに対するｈｉｖ−１株の耐性を逆転させる方法
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
EP0894498B1 (en) 1997-07-01 2006-05-17 Vicam, L.P. Method for sex determination of mammalian offspring
US7090839B2 (en) 2000-09-01 2006-08-15 Hidden Valley, N.V. Method of treatment of human immunodeficiency diseases
WO2003013544A1 (es) * 2001-08-08 2003-02-20 Laboratorios Químicos Industriales, S.A. Medicamento antiviral para utilizarse en el control de la enfermedad mancha blanca en camarones
EP2068906B1 (en) * 2006-09-19 2012-08-01 Sungkyunkwan University Foundation for Corporate Collaboration Antiviral agent against animal viruses
US20100130439A1 (en) * 2007-04-26 2010-05-27 Romesberg Floyd E Genomic mutation inhibitors that inhibit y family dna polymerases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4866035A (en) * 1987-10-05 1989-09-12 Merck & Co., Inc. Dipeptidyl saccharides as host resistance enhancers in AIDS-immuno-compromised hosts and methods of use

Also Published As

Publication number Publication date
JPH02142733A (ja) 1990-05-31
DE68900926D1 (de) 1992-04-09
EP0362162A3 (en) 1990-05-30
GR3004419T3 (es) 1993-03-31
EP0362162A2 (en) 1990-04-04
US5108993A (en) 1992-04-28
EP0362162B1 (en) 1992-03-04

Similar Documents

Publication Publication Date Title
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
DE69027216D1 (de) Transmukosale dosisform
HUT38256A (en) Process for producing combined pharmaceutical compositions containing xantine derivatives and o-acetyl-salicylic acid or pharmaceutically acceptables salts
MY130035A (en) Antiviral compounds
ES8800946A1 (es) Un procedimiento para preparar derivados de guanina
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
EP1369119B1 (en) Il-12 expression controlling agents
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
ES2038847T3 (es) Proceso para la preparacion de una composicion farmacutica conteniendo zidovudine e inosiplex para el tratamiento del sida y sindromes afines.
KR950702120A (ko) 골다공증 치료를 위한 포스포네이트의 용도(use of phosphonates for the treatment of osteoporosis)
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
EP0235151A1 (en) PROGLUMID AND ITS PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF NEOPLASTIC AFFECTIONS.
JPH08512311A (ja) 慢性疲労症候群治療用ヒ素医薬
AR006202A1 (es) Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene
KR890004705A (ko) 항바이러스성 제제
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
Zackheim et al. Treatment of psoriasis with 6‐thioguanine
US4436732A (en) Medicated compound for treating diseases infected by virus of the herpes group
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
GB2108383A (en) Compound and composition for use against herpes virus
JPS6466125A (en) Remedy for gastritis
JPS6368526A (ja) シアリルグリセライドからなる神経障害疾患治療剤

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 362162

Country of ref document: ES